---
title: "阿斯利康：第三阶段临床试验结果表明，重磅免疫治疗药物 Imfinzi（度伐利尤单抗，durvalumab）在主要终点上出现改善。"
description: "阿斯利康：第三阶段临床试验结果表明，重磅免疫治疗药物 Imfinzi（度伐利尤单抗，durvalumab）在主要终点上出现改善。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/242714610.md"
published_at: "2025-06-01T12:29:22.000Z"
---

# 阿斯利康：第三阶段临床试验结果表明，重磅免疫治疗药物 Imfinzi（度伐利尤单抗，durvalumab）在主要终点上出现改善。

阿斯利康：第三阶段临床试验结果表明，重磅免疫治疗药物 Imfinzi（度伐利尤单抗，durvalumab）在主要终点上出现改善。

### Related Stocks

- [AZN.US - 阿斯利康](https://longbridge.com/zh-CN/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Trump Strikes Again: AstraZeneca's Surprise Drug Deal Could Shake Big Pharma's Global Pricing Power | AstraZeneca has reached a drug-pricing deal with President Trump to reduce Medicaid drug prices, potentially reshaping B | [Link](https://longbridge.com/zh-CN/news/260941568.md) |
| ANALYSIS-AstraZeneca's US listing may pull other firms from London in its wake | AstraZeneca's decision to upgrade its U.S. listing while retaining its London presence may influence other UK firms to c | [Link](https://longbridge.com/zh-CN/news/259563996.md) |
| Short Interest in Schneider Electric SE (OTCMKTS:SBGSY) Drops By 16.8% | Schneider Electric SE (OTCMKTS:SBGSY) experienced a 16.8% decrease in short interest in January, with 197,858 shares sho | [Link](https://longbridge.com/zh-CN/news/276071356.md) |
| Are Wall Street Analysts Predicting Marriott International Stock Will Climb or Sink? | Are Wall Street Analysts Predicting Marriott International Stock Will Climb or Sink? | [Link](https://longbridge.com/zh-CN/news/276058991.md) |
| What to Expect from Palo Alto Networks's Earnings | Palo Alto Networks (NASDAQ:PANW) is set to release its quarterly earnings report on February 17, 2026, with analysts exp | [Link](https://longbridge.com/zh-CN/news/276061399.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。